Diverging trends in incidence and mortality, and improved survival of non-Hodgkin's lymphoma, in the Netherlands, 1989-2007

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 171-182

  van de Schans, S A M ^a   Issa, D E ^b   Visser, O ^c   Nooijen, P ^d   Huijgens, P C ^b   Karim Kos, H E ^e   Janssen Heijnen, M L G ^a,e   Coebergh, J W W ^a,e  

^a Eindhoven Cancer Registry   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Integraal Kankercentrum Amsterdam   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Incidence; Mortality; NHL; Population based; Survival; Trends

Indexed keywords

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NETHERLANDS; NONHODGKIN LYMPHOMA; PREVALENCE; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 84855166462     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr055     Document Type: Article

References (42)

1. Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumours of Haematopoietic and Lymfoid Tissues. Lyon, France: International Agency of Research on Cancer Scientific Publications 2008.
2. Curado MP, Edwards B, Shin HR et al. Cancer Incidence in Five Continents. Vol. IX. Lyon, France: International Agency of Research on Cancer Scientific Publications 2007; No 160.
3. Bosetti C, Levi F, Ferlay J et al. Incidence and mortality from non-Hodgkin lymphoma in Europe: the end of an epidemic? Int J Cancer 2008; 123: 1917-1923.
4. Clarke CA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002; 94: 2015-2023.
5. Carli PM, Coebergh JW, Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer 1998; 34: 2253-2263.
6. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008; 168: 469-476.
7. Sant M, Allemani C, Santaquilani M et al. EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931-991.
8. van de Schans SA, Gondos A, Van Spronsen DJ et al. Improving relative survival, but large remaining differences survival for non-Hodgkin's Lymphoma across Europe and the US from 1990 to 2004. J Clin Oncol 2011; 29(2): 192-199.
9. Sonneveld P, de Ridder M, van der Lelie H et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-2539.
10. Richtlijn non-Hodgkin lymfoom. Alphen ad Rijn, The Netherlands: Van Zuiden Communications BV 2004.
11. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
12. Gao G, Liang X, Jiang J et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol 2010; 49: 3-12.
13. Grillo-Lopez AJ, White CA, Varns C et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26: 66-73.
14. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ Bcell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
15. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with goodprognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
16. Groot MT, Lugtenburg PJ, Hornberger J et al. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005; 74: 194-202.
17. Adamson P, Bray F, Costantini AS et al. Time trends in the registration of Hodgkin and non-Hodgkin lymphomas in Europe. Eur J Cancer 2007; 43: 391-401.
18. Dundar Y, Bagust A, Hounsome J et al. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma. Health Technol Assess 2009; 13 (Suppl 1): 23-28.
19. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803-843.
20. Vidal L, Gafter-Gvili A, Leibovici L et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and metaanalysis of randomized trials. J Natl Cancer Inst 2009; 101: 248-255.
21. Kwong YL, Anderson BO, Advani R et al. Management of T-cell and naturalkiller-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009(10): 1093-1101.
22. Comprehensive Cancer Centres Netherlands. Dutch Cancer Registries. 2010; www.ikcnet.nl.
23. Fritz A, Percy C, Jack A et al. International Classification of Diseases for Oncology. Geneva, Switzerland: World Health Organization 2000.
24. Schouten LJ, Hoppener P, van den Brandt PA et al. Completeness of cancer registration in Limburg, the Netherlands. Int J Epidemiol 1993; 22: 369-376.
25. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001; 92: 1325-1330.
26. Brenner H, Gefeller O. An alternative approach to monitoring cancer patient survival. Cancer 1996; 78: 2004-2010.
27. Storm HH, Klint A, Tryggvadottir L et al. Trends in the survival of patients diagnosed with malignant neoplasms of lymphoid, haematopoietic, and related tissue in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol 2010; 49: 694-712.
28. Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma-a review. Acta Oncol 2006; 45: 258-271.
29. Rodriguez-Abreu D, Bordoni A, Zucca E. Epidemiology of hematological malignancies. Ann Oncol 2007; 18 (Suppl 1): i3-i8.
30. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52: 5432s-5440s.
31. Cartwright R, Brincker H, Carli PM et al. The rise in incidence of lymphomasin Europe 1985-1992. Eur J Cancer 1999; 35: 627-633.
32. Alexander DD, Mink PJ, Adami HO et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007; 120 (Suppl 12): 1-39.
33. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005; 25 (Suppl): 74-80.
34. Kanker in Nederland. Trends, prognoses en implicaties voor zorgvraag. Amsterdam, The Netherlands: KWF Kankerbestrijding-Signaleringscommissie Kanker 2004.
35. Luminari S, Cesaretti M, Rashid I et al. Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. Hematol Oncol 2007; 25(4): 189-197.
36. Krol AD, le Cessie S, Snijder S et al. Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma 2003; 44: 451-458.
37. Cronin-Fenton DP, Sharp L, Deady S, Comber H. Treatment and survival for non-Hodgkin's lymphoma: influence of histological subtype, age, and other factors in a population-based study (1999-2001). Eur J Cancer 2006; 42: 2786-2793.
38. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999; 78: 315-319.
39. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE et al. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol 2005; 129: 597-606.
40. Schaapveld M, Visser O, Siesling S et al. Improved survival among younger but not among older patients with multiple myeloma in the Netherlands, a population-based study since 1989. Eur J Cancer 2010; 46(1): 160- 169.
41. Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602.
42. Doorduijn JK, van der Holt B, van Imhoff GW et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003; 21: 3041-3050.